statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	547
SG - Singapore	124
IT - Italia	73
CN - Cina	72
VN - Vietnam	59
BR - Brasile	58
SE - Svezia	55
GB - Regno Unito	50
HK - Hong Kong	49
DE - Germania	39
FR - Francia	35
CI - Costa d'Avorio	30
BG - Bulgaria	25
IN - India	16
JP - Giappone	15
TR - Turchia	14
RU - Federazione Russa	12
SN - Senegal	11
NG - Nigeria	9
ES - Italia	7
ID - Indonesia	7
IQ - Iraq	7
CA - Canada	6
FI - Finlandia	5
PL - Polonia	4
AR - Argentina	3
BE - Belgio	3
EC - Ecuador	3
SA - Arabia Saudita	3
UA - Ucraina	3
VE - Venezuela	3
AE - Emirati Arabi Uniti	2
AT - Austria	2
BD - Bangladesh	2
CO - Colombia	2
GR - Grecia	2
IE - Irlanda	2
JO - Giordania	2
KG - Kirghizistan	2
LT - Lituania	2
MX - Messico	2
NL - Olanda	2
PH - Filippine	2
PT - Portogallo	2
SK - Slovacchia (Repubblica Slovacca)	2
ZA - Sudafrica	2
AO - Angola	1
AU - Australia	1
AZ - Azerbaigian	1
BB - Barbados	1
CG - Congo	1
CL - Cile	1
CR - Costa Rica	1
DZ - Algeria	1
EE - Estonia	1
EG - Egitto	1
HR - Croazia	1
IS - Islanda	1
KE - Kenya	1
KZ - Kazakistan	1
MO - Macao, regione amministrativa speciale della Cina	1
PE - Perù	1
SY - Repubblica araba siriana	1
TT - Trinidad e Tobago	1
TW - Taiwan	1
UZ - Uzbekistan	1
Totale	1.397

Nome	#
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports	158
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons	155
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)	140
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study	133
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact	133
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness?	132
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES	125
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy	117
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease	113
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments	110
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy	100
Totale	1.416

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	46	0	0	0	0	0	0	0	0	0	0	4	42
2021/2022	149	5	12	11	2	19	28	7	10	11	1	13	30
2022/2023	269	29	48	16	17	24	24	5	13	66	0	24	3
2023/2024	154	7	9	9	3	24	28	18	12	4	7	23	10
2024/2025	392	3	13	6	33	35	69	16	14	35	58	34	76
2025/2026	387	46	28	27	17	61	26	87	15	38	42	0	0
Totale													1.416

CINECA IRIS Institutional Research Information System